CJC 1295 No DAC Research

CJC-1295 No DAC 10 mg (mod GRF 1-29) is supplied by Healthy Peps as a lyophilized research peptide for in vitro growth-hormone axis studies, with batch documentation and Canada-wide shipping.

Physicochemical Reference Data

Mechanism & Research Context

CJC-1295 No DAC is the short-acting member of the GRF analog family: a GRF(1-29) sequence carrying four substitutions that increase resistance to enzymatic degradation while removing the drug-affinity-complex moiety that gives the DAC version its long albumin-bound half-life. That distinction is the whole point of the compound in research settings, where a rapidly cleared growth-hormone-releasing-factor analog is often preferable to a week-long exposure.

Published growth-hormone research uses GRF(1-29) analogs to probe GHRH receptor activation, downstream GH release from pituitary cell preparations, and the pulsatile architecture of the GH/IGF-1 axis. The short clearance profile makes this analog useful in washout experiments, because the compound is cleared on a timescale compatible with sequential treatments in the same culture system.

The tetrasubstituted sequence is frequently studied alongside ghrelin-receptor compounds such as ipamorelin, because the two act through distinct receptors (GHRH receptor versus GHS-R1a) on the same endocrine pathway. Research designs that combine both mechanisms usually report them as complementary rather than redundant.

The 10 mg vial is the working size for most in vitro protocols, and every Healthy Peps vial carries the batch number used on its Certificate of Analysis.

How It Compares to Related Peptides

The No DAC version is cleared far faster than CJC-1295 with DAC, which binds albumin and persists for days. If your protocol measures acute GHRH receptor stimulation or requires a defined washout window, the No DAC analog is the appropriate choice; if you need sustained exposure across a multi-day culture, the DAC version is used instead.

Reconstitution, Stability & Handling

Reconstitute with bacteriostatic water, adding the diluent slowly against the vial wall and swirling to dissolve. Avoid vortexing or vigorous shaking. Store reconstituted material refrigerated and use within the period defined by your protocol. Lyophilized vials should be kept at −20 °C, protected from light and moisture.

Selected Reading & Research Notes

• GRF(1-29) analog pharmacology literature. Describes enzymatic-stability modifications at positions 2, 8, 15 and 27 relative to native GRF(1-29).
• Comparative GHRH / ghrelin receptor research. Reports distinct receptor pathways for GRF analogs and GHS-R1a agonists such as ipamorelin.

Frequently Asked Questions